新药许可交易模糊综合评价研究

发布时间：2018-02-28 02:19

本文关键词： 新药研发许可交易专家赋权层次分析法模糊综合评价法　出处：《华东师范大学》2017年硕士论文　论文类型：学位论文

【摘要】：新药研发是一项涉及多领域、多学科的系统工程,具有长周期、高投入、高风险、高回报的特点。许可交易由于可以使企业直接获得新药研究成果,为之节省大量的时间、资金、风险成本,正越来越收到企业的重视。目前针对新药许可交易的评价多集中于估值研究,关于立项阶段的评价则多以自主研发这一模式为基础。本文针对许可交易这一特定模式,设立了综合考虑新药研发特点与许可交易特性的指标体系,运用层次分析法进行各层级指标权重确认,运用客观定权法为群组决策中的专家意见进行赋权,运用模糊综合评价建立了数学模型,最终为实施新药许可业务的企业提供了一种实用性较强的立项评价工具。本文共分为六个章节。首章为绪论,简述研究背景、意义和方法及框架,并给出研究的创新点;第二章分别介绍新药研发的相关概念以及评价方法研究综述;第三章通过对行业背景的分析,阐述了新药研发对于中国医药企业的意义所在,并展示了中外新药研发的现状;第四章介绍新药研发的特点及途径,详细展示了模糊综合评价模型的构建;第五章以K公司D项目的许可评价为例,进行实证分析;第六章为小结部分,主要讨论了本文的研究结论和局限性,以及未来进一步的研究方向。
[Abstract]:New drug research and development is a multi-domain, multidisciplinary system engineering with the characteristics of long period, high investment, high risk, high return. Capital, risk costs, are getting more and more attention from enterprises. At present, most of the evaluation of new drug licensing transactions is focused on valuation research. The evaluation of the stage of project establishment is based on the model of independent R & D. In this paper, an index system considering the characteristics of new drug research and development and the characteristics of licensing transaction is set up in view of the specific model of licensing transaction. The weight of index is confirmed by AHP, the expert opinion in group decision is weighted by objective weight method, and the mathematical model is established by fuzzy comprehensive evaluation. Finally, it provides a practical evaluation tool for the enterprises carrying out the new drug licensing business. This paper is divided into six chapters. The first chapter is the introduction, briefly describes the research background, significance, methods and framework, and gives the innovative points of the research. The second chapter introduces the related concepts and evaluation methods of new drug research and development, the third chapter describes the significance of new drug research and development for Chinese pharmaceutical enterprises through the analysis of industry background, and shows the current situation of new drug research and development at home and abroad. Chapter 4th introduces the characteristics and approaches of new drug research and development, and demonstrates the construction of fuzzy comprehensive evaluation model in detail. Chapter 5th takes the licensing evaluation of D project of K Company as an example to carry out empirical analysis. Chapter 6th is a summary. This paper mainly discusses the research conclusions and limitations, as well as the future direction of further research.
【学位授予单位】：华东师范大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：F224;F426.72

【参考文献】